Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2017-03-01
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topcon DRI OCT Triton With SS-OCT Angio Software Evaluation Study
NCT04201340
Triton Fundus Autofluorescence and Fluorescein Angiography
NCT03107104
OCT Reference Database
NCT01986478
OCT Image Quality Performance Evaluation
NCT02991027
Clinical Validation of New OCT System
NCT01809704
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects Presenting With Normal Eyes
Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
Topcon DRI OCT Triton (plus)
OCT Machine used for diagnostic purposes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topcon DRI OCT Triton (plus)
OCT Machine used for diagnostic purposes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
3. Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable)
4. IOP ≤ 21 mmHg bilaterally
5. BCVA 20/40 or better bilaterally
Exclusion Criteria
2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images
3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33%
4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:
1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
2. Glaucoma hemi-field test "outside normal limits."
5. Narrow angle
6. History of leukemia, dementia or multiple sclerosis
7. Concomitant use of hydroxychloroquine and chloroquine
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Topcon Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Riesman, MS
Role: STUDY_CHAIR
Topcon Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern California College of Optometry
Anaheim, California, United States
Accessoreyes Optometry
Pasadena, California, United States
Illinois College of Optometry
Chicago, Illinois, United States
Fischer Laser Eye Center
Willmar, Minnesota, United States
New York VA
Jamaica, New York, United States
Stat University of New York College of Optometry
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Triton RDB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.